期刊文献+

人二倍体细胞狂犬疫苗两种纯化方式比较分析

Comparative analysis of two purification methods of human diploid cell rabies vaccine
原文传递
导出
摘要 目的评价人二倍体细胞狂犬疫苗两种纯化方式的效果。方法比较分析分子筛层析柱法和密度梯度离心法两种纯化方式得到的狂犬病毒纯化液的抗原回收率、蛋白含量和主要杂质去除率来判断这两种方式的纯化效果。结果分子筛层析柱法得到的纯化液抗原回收率均值为69.8%,蛋白含量均值为179.27μg/mL,牛血清白蛋白去除率高于99.98%;密度梯度离心法得到的纯化液抗原回收率均值为76.7%,蛋白含量均值为144.82μg/mL,牛血清白蛋白去除率高于99.98%。结论两种方式得到的狂犬病毒纯化液都符合要求,但是密度梯度离心法的总蛋白含量低、抗原回收率高,相较于分子筛层析柱法纯化效果更佳。 Objective To evaluate the efficacy of two purification methods of human diploid cell rabies vaccine.Methods By analyzing and comparing the protein content,antigen recovery rate and main impurity removal rate of the virus purification solution obtained by density gradient centrifugation and chromatography column purification,the purification efficiency of the two purification methods was evaluated.Results Based on the method of density gradient centrifugation purification,the average antigen recovery rate and protein content were 69.8% and 179.27μg/mL,respectively,and the removal rate of bovine serum albumin was higher than 99.98%.Based on the method of chromatography column purification,the average antigen recovery rate and protein content were 76.7% and 144.82μg/mL,respectively,and the removal rate of bovine serum albumin(BSA)was higher than 99.98%.Conclusion The antigen content,protein content and BSA residue of the purified solution obtained by the two methods all meet the requirements of the pharmacopoeia.However,the density gradient centrifugation purification method has a lower total protein content and a higher antigen recovery rate,and has a better effect than the chromatography column purification method.
作者 赵鹭 左静 刘海文 ZHAO Lu;ZUO Jing;LIU Haiwen(Beijing Minhai Biotechnology Co.,LTD,Daxing,Beijing,102600,China)
出处 《河南预防医学杂志》 2022年第9期669-672,共4页 Henan Journal of Preventive Medicine
关键词 狂犬病疫苗 分子筛层析柱纯化 密度梯度离心纯化 Rabies vaccine Chromatographic column purification Density gradient centrifugation purification
  • 相关文献

参考文献7

二级参考文献63

  • 1罗明,张茂林,涂长春.我国狂犬病流行状况分析及防治对策[J].中国人兽共患病杂志,2005,21(2):188-190. 被引量:136
  • 2李振平.提高血液制品病毒安全性的途径[J].微生物学免疫学进展,1996,24(1):83-85. 被引量:1
  • 3俞永新.国内外狂犬病疫苗的发展和现状[J].上海预防医学,2006,18(5):216-218. 被引量:27
  • 4Guidelines on viral inactivation and removal procedures intended to assure the viral safety of human blood plasma products. WHO Technical Report Series. 924. 2004.
  • 5Williamson LM, Allain JP. Virally inactivated fresh frozen plasma. Vox Sang, 1995,69:159-165.
  • 6国家食品药品监督管理局.预防用疫苗临床试验不良反应分级标准指导原则[s].2005.10.14.
  • 7左永波,杜松涛,钱燕玲,赵广军,李江.精制抗狂犬病血清的接种反应[J].中国生物制品学杂志,2007,20(12):930-931. 被引量:5
  • 8Vodopija RS,Lafont M,Baklaic Z,et al.Persistence of humoral immunity to rabies 1100 days after immunization and effect of a single booster dose of rabies vaccine[J].Vaccine,1997,15(5):571-574.
  • 9Vodopija I,Sureau P,Smerdel S,et al.Interaction of rabies vaccine with human rabies immunoglobulin and reliability of a2-1-1 schedule application for postexposure treatment[J].Vaccine,1988,6(3):283-286.
  • 10Vodopija I,Sureaut P,Smerdel S,et al.Comparative study of two human diploid rabies vaccines administered with antirabies globulin[J].Vaccine,1988,6(6):489-490.

共引文献142

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部